Far East Bio-Tec. Co., Ltd.

As of June 30, 2026, Far East Bio-Tec. Co., Ltd. carries a market capitalization of 1.53B, placing it among publicly traded companies globally. Its enterprise value stands at 1.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Far East Bio-Tec. Co., Ltd. has 34.99M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Far East Bio-Tec. Co., Ltd. maintains a current ratio of 5.16, meaning it holds 5.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Far East Bio-Tec. Co., Ltd.'s stock has declined approximately 3.71% over the past 52 weeks. The 50-day moving average sits at 41.54, while the 200-day moving average is 43.41.

As of June 30, 2026, Far East Bio-Tec. Co., Ltd. holds 276.41M in cash and equivalents against 57.25M in total debt, resulting in a net debt position of -242.71M. Total book value stands at 603.08M, with working capital of 368.67M providing operational flexibility.

Far East Bio-Tec. Co., Ltd.'s most recent stock split took place on August 28, 2026 with a 10:11 split ratio.